Home › Compare › ASTGY vs ABBV
ASTGY yields 11.11% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 4
Combined, ASTGY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ASTGY + ABBV for your $10,000?
Hong Kong Aerospace Technology Group Limited, an investment holding company, provides electronics manufacturing services in the People's Republic of China, the United States, India, South Korea, Austria, Hong Kong, Brazil, Mexico, the United Kingdom, Germany, Vietnam, and Australia. The company provides design enhancement and verification; technical advice and engineering solutions; raw materials selection and procurement; quality control; logistic and delivery; and after-sale services for assembling and production of printed circuit board assemblies and fully-assembled electronic products for banking and finance, telecommunication, and smart device industries. Its fully-assembled electronic products include mobile phones, mobile point-of-sale, photovoltaic inverters, tablets, and street lamp controllers. It is also engaged in the sales of electronic products, satellite manufacturing, and satellite tracking and controlling services. Hong Kong Aerospace Technology Group Limited has a strategic cooperation agreement with the College of Engineering of City University of Hong Kong for the research and development of advanced satellite technology and related applications, such as communication systems, antenna technology, advanced materials, data processing, and energy management in Hong Kong. The company was formerly known as Eternity Technology Holdings Limited and changed its name to Hong Kong Aerospace Technology Group Limited in June 2021. The company was incorporated in 2003 and is based in Tseung Kwan O, Hong Kong. Hong Kong Aerospace Technology Group Limited is a subsidiary of Hong Kong Aerospace Technology Holdings Limited.
Full ASTGY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.